Update on the “Raising Arizona” Metaphor Missing Patent for OSENI

Back in October I blogged about an Orange Book listed patent, 6,329,404, that disappeared from the Orange Book for one of six strengths of Takeda’s OSENI® (alogliptin benzoate/pioglitazone HCl). The FDA had apparently not updated the expiration date for the 12.5/45mg strength (Prod. No. 006) when Takeda filed their 3542 form to inform the agency that their patent had received a Patent Term Extension (“PTE”). The patent’s expiration date had been updated for the five other OSENI strengths. So when the 2017 Orange Book was prepared, the FDA deleted the ‘404 patent from Prod. No. 006 due to its original, unextended expiration date in 2016 still being shown.

In addition to my blog posting, I made a phone call and sent an email to the Takeda contact person listed on their 3542 form. However, I never received a response. So I decided to take the bull by the horns and let the Orange Book Staff know about the missing patent. Unfortunately, this was about the same time as my wife and I were going through all of the work needed to sell our house in NJ and get ready to move back to Bucks County, PA which we had left twenty-eight years earlier. By the time I came up for air after our move it was already New Year’s Day.

So I sent an email to the Orange Book Staff while waiting for some bowl game or other to start. I described the situation and attached the two Takeda 3542 forms that I had received from the FDA as a result of a FOIA request (the second of the two was apparently only submitted to correct the contact person’s email address). And then I waited to see what would happen.

On January 9 I decided to check the OSENI Prod. No. 006 patent listings to see if anything had happened. Lo and behold, the ‘404 patent was listed with its extended expiration date! Yay! And today (January 10) I received an email from the Orange Book Staff confirming that they had updated the Orange Book and  thanking me for letting them know about this matter.

So now I can saddle up my trusty steed and ride off into the sunset knowing that my work here is done.

Comments

Post a Comment

Popular posts from this blog

Orange Book Vol. 42/Supp. 6 News: Watch out for the breadth of your use codes

This posting is late since I am talking about Vol. 42, Supp. 6 of the Orange Book. The data for Supp. 6 was released by the FDA in mid-July. However, I updated my  Orange Book Companion  immediately when the data was released, so my subscribers received the new data on time. Similarly, if you are not a subscriber but enjoy checking out my free  Orange Book Companion  “ What’s New ” each month, that was also ready to view in mid-July. So, what is late? It’s this Supp. 6 news where I discuss a mass delisting of patents for a single product   in which all of the patents had what appears to be overly broad use codes . Please read on.   Supp. 6 added 52 new patents to the FDA’s Orange Book. However, unlike Supp. 5, there were a number of patents that were delisted or were newly tagged as being the subject of a delisting request. Two of four patents listed for Serenity Pharmaceuticals’ NOCTIVA ( desmopressin acetate)   were delisted. Both strengths of NOCTIVA are shown in the Orange Book as
Read more

Orange Book V43, Supp. 1 news

  Happy Orange Book New Year! Volume 43, Supp. 1 added 41 new patents to the FDA’s Orange Book. That includes three new patents for the current patent listing champ, AUVELITY® which now has 103 patents listed. You can see all of the changes to the Orange Book that occurred in Vol. 43/Supp. 1 by going to the Orange Book Companion® public home page and clicking on the prominent “What’s New” link.  If are a gluten for punishment, can also see all 103 AUVELITY patents by clicking the sample link for trademarks that begin with "A" and then scrolling down to AUVELITY. A device for making a drug does not claim the drug, itself Three particularly interesting patents were listed in the Orange Book as part of Volume 43/Supplement 1. All three patents claim devices for making the approved drug. They do not claim the approved drug, itself, or a method of using the approved drug. Yet all three were listed as “drug product” patents.  In each case, the approved product is a gas that is con
Read more

Make sure that your patent exists before submitting a 3542 form for the patent to the FDA

 So, you received an “Issue Notification” from the USPTO for an allowed patent application. Yay! But be careful! The “Issue Notification” document that the USPTO sent you says that it merely contains a “ projected ” patent number and issue date.  In the case of MC2 Therapeutics’ WYNZORA, a patent with the projected patent number that the Issue Notification contained did not issue on the projected issue date, and, in fact, never issued! However, MC2 must have submitted a 3542 form to the FDA for patent number 11638711 (‘711 patent) that was contained in an Issue Notification that had been sent to them on April 12, 2023. That Issue Notification said that the patent would issue on May 2, 2023. The Electronic Orange Book shows that information for the ‘711 patent was received by the FDA for WYNZORA on May 31. However, in my preparation for the Vol. 43/ Supplement 6 version of my Orange Book Companion® I discovered that one of the text files of basic data that my algorithms had generated fo
Read more